PositiveID’s ExcitePCR Subsidiary to Present and Exhibit at the Seed Central Tech Showcase on January 11th

Seed Central Showcase facilitates research collaboration between the seed and agbiotech industry and UC Davis to bring science to market faster

Kimothy Smith, DVM, EVP and Chief Science Officer of ExcitePCR, will discuss how the company’s FireflyDX can be used for agricultural screening

DELRAY BEACH, Fla., Jan. 03, 2018 -- PositiveID Corporation (“PositiveID” or “Company”) (OTC:PSID), a life sciences company focused on detection and diagnostics, announced today that its ExcitePCR Corporation subsidiary, will present and exhibit at the Seed Central Tech Showcase on Thursday, January 11, 2018, at the University of California, Davis Conference Center.  Kimothy L. Smith, DVM PhD, EVP and Chief Science Officer of ExcitePCR, will discuss how the company’s FireflyDX technology can be used for agricultural screening and food safety testing.  

PositiveID previously announced its FireflyDX polymerase chain reaction (“PCR”) breadboard prototype pathogen detection system (“prototype system”) successfully detected genetically modified organisms (“GMOs”), specifically corn and soybeans, during a pilot study with seqID inc. The pilot study evaluated the use of FireflyDX to detect genetically modified corn and soybeans at seaports where corn and soybeans are being shipped to countries that limit the percentage of GMOs in the shipment that may be imported.  During the lab-based testing, the FireflyDX prototype system detected GMOs in corn and soybeans at amounts below 1%.  This level of detection could be useful for stopping shipments containing even very low quantities of GMOs to countries that prohibit them.

PositiveID, through its ExcitePCR Corporation subsidiary, is developing the FireflyDX family of products, automated pathogen detection systems for rapid diagnostics at the point-of-care/point-of-need (“POC/PON”). The FireflyDX family products, consisting of the FireflyDX-Portable™ and the FireflyDX-Handheld™, are designed to be lab quality, real-time devices able to detect pathogens faster and less expensively than existing systems. FireflyDX’s applications include POC/PON detection of pathogenic organisms; agricultural and food screening in both domestic sectors and developing countries; and detection of biological agents associated with weapons of mass destruction.

About Seed Central
Seed Central is a public-private partnership. Its purpose is to energize the seed and agbiotech industry cluster surrounding UC Davis and to contribute to the economic development in the region and beyond. Seed Central facilitates communication & research collaboration between the seed and agbiotech industry and UC Davis to bring science to market faster. UC Davis is a world leader in seed, plant and agricultural sciences. Established in 2010, Seed Central is an initiative of the Seed Biotechnology Center at UC Davis and SeedQuest, joined by a growing number of companies and organizations in the global seed and food industry.

About PositiveID Corporation
PositiveID Corporation is a life sciences tools and diagnostics company with an extensive patent portfolio. PositiveID develops biological detection and diagnostics systems, specializing in the development of microfluidic systems for the automated preparation of and performance of biological assays. PositiveID is also a leader in the mobile technology vehicle market, with a focus on the laboratory market and homeland security. For more information on PositiveID, please visit http://www.psidcorp.com, or connect with PositiveID on Twitter, Facebook or LinkedIn.

Statements about PositiveID's future expectations, including the likelihood that the FireflyDX technology can be used for agricultural screening and food safety testing; the likelihood that this level of detection could be useful for stopping shipments containing even very low quantities of GMOs to countries that prohibit them; the likelihood that FireflyDX’s applications include POC/PON detection of pathogenic organisms, agricultural and food screening in both domestic sectors and developing countries, and detection of biological agents associated with weapons of mass destruction; constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and PositiveID's actual results could differ materially from expected results. These risks and uncertainties include, without limitation, the Company’s ability to target the specialty vehicle market; the Company’s ability to attract new customers and retain existing customers; the Company’s ability to target the professional healthcare market; the Company’s ability to raise capital; the Company’s ability to complete the testing and development of FireflyDX; as well as other risks. Additional information about these and other factors that could affect the Company's business is set forth in the Company's various filings with the Securities and Exchange Commission, including those set forth in the Company's 10-K filed on March 31, 2017, and 10-Qs filed on November 13, 2017, August 14, 2017, and May 15, 2017, under the caption "Risk Factors." The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.

Contact:
PositiveID Corporation
Allison Tomek
(561) 805-8044
[email protected]